NZ799031A - Solid forms of berberine ursodeoxycholate and compositions and methods thereof - Google Patents
Solid forms of berberine ursodeoxycholate and compositions and methods thereofInfo
- Publication number
- NZ799031A NZ799031A NZ799031A NZ79903118A NZ799031A NZ 799031 A NZ799031 A NZ 799031A NZ 799031 A NZ799031 A NZ 799031A NZ 79903118 A NZ79903118 A NZ 79903118A NZ 799031 A NZ799031 A NZ 799031A
- Authority
- NZ
- New Zealand
- Prior art keywords
- solid forms
- methods
- compositions
- berberine ursodeoxycholate
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710335467.5A CN108864077B (zh) | 2017-05-12 | 2017-05-12 | 小檗碱有机酸盐的固体形式及其制备方法 |
| NZ759154A NZ759154B2 (en) | 2018-05-11 | Solid forms of berberine ursodeoxycholate and compositions and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ799031A true NZ799031A (en) | 2026-02-27 |
Family
ID=64105207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ799031A NZ799031A (en) | 2017-05-12 | 2018-05-11 | Solid forms of berberine ursodeoxycholate and compositions and methods thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10959999B2 (https=) |
| EP (2) | EP4234568A3 (https=) |
| JP (3) | JP7685314B2 (https=) |
| KR (2) | KR102761338B1 (https=) |
| CN (1) | CN108864077B (https=) |
| AU (2) | AU2018264384B2 (https=) |
| CA (1) | CA3062833A1 (https=) |
| EA (1) | EA201992607A1 (https=) |
| ES (1) | ES2988672T3 (https=) |
| NZ (1) | NZ799031A (https=) |
| WO (1) | WO2018205987A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108864077B (zh) * | 2017-05-12 | 2020-05-22 | 深圳君圣泰生物技术有限公司 | 小檗碱有机酸盐的固体形式及其制备方法 |
| CN110954645B (zh) * | 2019-09-09 | 2020-09-29 | 山东琪康生物技术有限公司 | 一种高质量四黄止痢颗粒的检测方法 |
| CN112851660B (zh) * | 2019-11-12 | 2022-03-18 | 广东药科大学 | 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途 |
| KR102636847B1 (ko) * | 2020-09-18 | 2024-02-19 | 경북대학교 산학협력단 | 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물 |
| CN111920777A (zh) * | 2020-09-18 | 2020-11-13 | 四川迪菲特药业有限公司 | 一种盐酸小檗碱片及其制备方法 |
| US20230112845A1 (en) * | 2020-10-23 | 2023-04-13 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia |
| WO2022083713A1 (en) * | 2020-10-23 | 2022-04-28 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions of berberine ursodeoxycholate and methods thereof for treating fatty liver disease, diabetes and hyperlipidemia |
| WO2022161468A1 (en) * | 2021-01-28 | 2022-08-04 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis |
| US20230346803A1 (en) * | 2021-01-28 | 2023-11-02 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis |
| WO2023088463A1 (en) * | 2021-11-22 | 2023-05-25 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions |
| CN115710263A (zh) * | 2021-12-02 | 2023-02-24 | 山西医科大学 | 小檗碱新盐的晶型及其制备方法 |
| CN114716498B (zh) * | 2022-01-20 | 2024-01-23 | 成都贝诺科成生物科技有限公司 | 一种高稳定性的失碳熊去氧胆酸小檗碱盐晶型及其制备方法 |
| CN115477647A (zh) * | 2022-10-26 | 2022-12-16 | 山西医科大学 | 小檗碱富马酸盐晶型及其制备方法和其组合物与应用 |
| WO2024120452A1 (en) * | 2022-12-07 | 2024-06-13 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods for prophylaxis and treatment of covid-19 |
| TW202432104A (zh) * | 2022-12-30 | 2024-08-16 | 大陸商深圳君聖泰生物技術有限公司 | 藥物組合、藥物組合物及其應用 |
| CN120659782A (zh) * | 2023-02-15 | 2025-09-16 | 深圳君圣泰生物技术有限公司 | 小檗碱牛磺熊去氧胆酸盐组合物及其方法 |
| WO2024179570A1 (en) * | 2023-03-01 | 2024-09-06 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods for treating severe hypertriglyceridemia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| WO2007005644A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| CA2616383C (en) | 2005-07-29 | 2015-06-09 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| CN102229636A (zh) * | 2011-04-21 | 2011-11-02 | 东北林业大学 | 小檗碱9位酯键偶合胆酸的新衍生物及其制备方法 |
| US9597337B2 (en) * | 2014-04-04 | 2017-03-21 | North American Biomedical Research Center Usa, Inc. | Berberine-ursodeoxycholic acid conjugate for treating the liver |
| CA2945609C (en) | 2014-07-29 | 2023-05-23 | Shenzhen Hightide Biopharmaceutical, Ltd. | Berberine-ursodeoxycholic salt, method of preparation and application therof |
| CN105693805A (zh) * | 2016-03-15 | 2016-06-22 | 合肥华方医药科技有限公司 | 一种胆酸类小檗碱偶合物的制备及医药用途 |
| CN108864077B (zh) * | 2017-05-12 | 2020-05-22 | 深圳君圣泰生物技术有限公司 | 小檗碱有机酸盐的固体形式及其制备方法 |
-
2017
- 2017-05-12 CN CN201710335467.5A patent/CN108864077B/zh active Active
-
2018
- 2018-05-11 EP EP23167629.7A patent/EP4234568A3/en active Pending
- 2018-05-11 CA CA3062833A patent/CA3062833A1/en active Pending
- 2018-05-11 US US16/608,457 patent/US10959999B2/en active Active
- 2018-05-11 EA EA201992607A patent/EA201992607A1/ru unknown
- 2018-05-11 EP EP18798004.0A patent/EP3625229B9/en active Active
- 2018-05-11 KR KR1020197036227A patent/KR102761338B1/ko active Active
- 2018-05-11 KR KR1020257002617A patent/KR20250017765A/ko active Pending
- 2018-05-11 AU AU2018264384A patent/AU2018264384B2/en active Active
- 2018-05-11 ES ES18798004T patent/ES2988672T3/es active Active
- 2018-05-11 WO PCT/CN2018/086461 patent/WO2018205987A1/en not_active Ceased
- 2018-05-11 JP JP2019562655A patent/JP7685314B2/ja active Active
- 2018-05-11 NZ NZ799031A patent/NZ799031A/en unknown
-
2021
- 2021-02-23 US US17/182,715 patent/US12138258B2/en active Active
-
2022
- 2022-07-18 AU AU2022206685A patent/AU2022206685B2/en active Active
-
2023
- 2023-02-13 JP JP2023020228A patent/JP7728295B2/ja active Active
-
2024
- 2024-10-02 US US18/904,564 patent/US20250099456A1/en active Pending
-
2025
- 2025-08-12 JP JP2025134447A patent/JP2025183212A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3625229B1 (en) | 2024-07-31 |
| EP3625229B9 (en) | 2024-10-09 |
| CN108864077B (zh) | 2020-05-22 |
| EP3625229A4 (en) | 2021-03-03 |
| JP2025183212A (ja) | 2025-12-16 |
| AU2022206685A1 (en) | 2022-08-11 |
| US20210251981A1 (en) | 2021-08-19 |
| AU2022206685B2 (en) | 2024-05-02 |
| CA3062833A1 (en) | 2018-11-15 |
| JP7685314B2 (ja) | 2025-05-29 |
| EP3625229C0 (en) | 2024-07-31 |
| JP2020519654A (ja) | 2020-07-02 |
| NZ759154A (en) | 2024-07-26 |
| EP4234568A2 (en) | 2023-08-30 |
| JP7728295B2 (ja) | 2025-08-22 |
| ES2988672T3 (es) | 2024-11-21 |
| US20200188387A1 (en) | 2020-06-18 |
| CN108864077A (zh) | 2018-11-23 |
| EA201992607A1 (ru) | 2020-06-29 |
| US10959999B2 (en) | 2021-03-30 |
| KR20250017765A (ko) | 2025-02-04 |
| US20250099456A1 (en) | 2025-03-27 |
| KR102761338B1 (ko) | 2025-02-04 |
| WO2018205987A1 (en) | 2018-11-15 |
| KR20230017930A (ko) | 2023-02-07 |
| EP4234568A3 (en) | 2024-01-03 |
| AU2018264384B2 (en) | 2022-05-19 |
| EP3625229A1 (en) | 2020-03-25 |
| US12138258B2 (en) | 2024-11-12 |
| AU2018264384A1 (en) | 2019-12-12 |
| JP2023104925A (ja) | 2023-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ799031A (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
| MX2025009223A (es) | Agentes de union a clec9a y su uso | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| PH12019501339A1 (en) | Amino acid compositions and methods for the treatment of muscle diseases and disorders | |
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| IN2015DN00376A (https=) | ||
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| PH12021550872A1 (en) | Therapeutic compounds | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| EP4603148A3 (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| MY201535A (en) | Therapeutic compounds | |
| MX2018000262A (es) | Usos terapeuticos de formulaciones de berberina. | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| PH12021550903A1 (en) | Novel pyridazines | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| PH12017501693A1 (en) | Compositions for the treatment of kidney and/or liver diseases | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| HK40013671A (en) | Amino acid compositions and methods for the treatment of muscle diseases and disorders | |
| MY203647A (en) | Sustained-release dosage forms of ruxolitinib |